MuReva Phototherapy completes NIH Commercialization Accelerator Program
MuReva Phototherapy has announced that the company has completed the National Institutes of Health (NIH) Commercialization Accelerator Program (CAP) which is only available for Phase II SBIR & STTR Awardees. The NIH CAP is a 9-month program run by the Larta Institute that enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.
Offered since 2004, the NIH CAP is designed to address the needs and commercialization objectives of companies across the spectrum of experience and stages. Over 1000 companies, who have received a PSBIR/STTR Phase II, have participated in the CAP to date, with only 80 companies selected each year for participation. The program provides companies access to a combination of deep domain expertise and industry connections. MuReva Phototherapy is grateful to have been selected by the NIH to participate in this program.